ArticleProceedings of the National Academy of Sciences of the United States of America2019
Antidepressant-relevant concentrations of the ketamine metabolite (2
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05864053 (), which is not on this map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05864053 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation
(2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.
Who cites it
92 citing papers in PubMed, 156 citations in OpenAlex.
- A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.Clinical pharmacology and therapeutics · 2024Trial
- Acute Dissociation and Ketamine's Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial.The international journal of neuropsychopharmacology · 2024Trial
- Sex-dependent metabolism of ketamine and (Journal of psychopharmacology (Oxford, England) · 2022Trial
- Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- From depression to bone health: examining the skeletal effects of classical and rapid-acting antidepressants.The international journal of neuropsychopharmacology · 2026Review
- The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal.Psychopharmacology · 2026Article
- Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular psychiatry · 2026Article
- Ionic Homeostasis Failure in Major Depressive Disorder: Ion Channel Mechanisms, Excitation-Inhibition Imbalance, and Precision Therapeutics.International journal of molecular sciences · 2026Review
- A Time-Sensitive Plasticity Distinguishes the Rapid and Sustained Synaptic Actions of Ketamine from Its (2The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings.Healthcare (Basel, Switzerland) · 2026Review
- Prefrontal contribution to passive coping behaviour in chronic stress and treatment by fast-acting antidepressant.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- D-serine: A Multitalented Neuromodulator in Brain Function, Systemic Homeostasis, and Disease.Cellular and molecular neurobiology · 2026Review
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- An Overview of Depression Pathogenesis: Prevailing Hypotheses and Associated Neurobiological Underpinnings Primarily Evidenced by Rodent Studies.Depression and anxiety · 2026Review
- Review
- Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression.European archives of psychiatry and clinical neuroscience · 2025Review
- Mechanism of antidepressant action of ketamine and differences between its two enantiomers.Journal of anesthesia and translational medicine · 2025Review
- Bioactive ketamine metabolite exerts in vivo neuroplastogenic effects to improve hippocampal function in a treatment-resistant depression model.Cell reports · 2025Article
- Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.Biological psychiatry · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Eric W LumsdenDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201.
Timothy A TroppoliDepartment of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201.
Scott J MyersDepartment of Pharmacology, Emory University, Atlanta, GA 30329.
Panos ZanosDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201.
Yasco AracavaDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201.
Jan KehrDepartment of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Jacqueline LovettBiomedical Research Center, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224.
Sukhan KimDepartment of Pharmacology, Emory University, Atlanta, GA 30329.
Fu-Hua WangDepartment of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Staffan SchmidtDepartment of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Carleigh E JenneDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201.
Peixiong YuanSection on the Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892.
Patrick J MorrisDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Intramural Research Program, National Institutes of Health, Bethesda, MD 20892.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Intramural Research Program, National Institutes of Health, Bethesda, MD 20892.
Carlos A ZarateSection on the Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892.
Ruin MoaddelBiomedical Research Center, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224.
Stephen F TraynelisDepartment of Pharmacology, Emory University, Atlanta, GA 30329.
Edna F R PereiraDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201.
Scott M ThompsonDepartment of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201.
Edson X AlbuquerqueDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201.
Todd D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201; gouldlab@me.com.ORCID 0000-0003-1511-7183
University of Maryland, Baltimore · USNational Institutes of Health · USEmory University · USKarolinska Institutet · SEInstitute on Aging · US
Funding
Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2MStress, Depression, Serotonin, and Plasticity of Excitatory TransmissionR01MH086828 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI THOMPSON, SCOTT M. · 2010 to 2019
$3.8MMechanism of Action of Novel Subunit-Selective NMDA Receptor ModulatorsR01NS065371 · NINDS · EMORY UNIVERSITY · PI TRAYNELIS, STEPHEN F · 2009 to 2018
$3.4MAn Upright Multiphoton Microscope for an Established Core Imaging FacilityS10OD010352 · OD · UNIVERSITY OF MARYLAND BALTIMORE · PI BLANPIED, THOMAS A · 2012 to 2012
$600kA Zeiss Duo Confocal Microscope for Shared Imaging FacilityS10RR024548 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI BLANPIED, THOMAS A · 2008 to 2008
$500kHydroxynorketamine for the Treatment of PTSD and AnhedoniaI01BX004062 · VA · BALTIMORE VA MEDICAL CENTER · PI GOULD, TODD D · 2019 to 2023
–BLRD VA I01 BX004062NCRR NIH HHS S10 RR024548NIH HHS S10 OD010352NIMH NIH HHS R01 MH086828NIMH NIH HHS R01 MH107615NINDS NIH HHS R01 NS065371
Abstract
Preclinical studies indicate that (2
Indexed as
AnimalsAntidepressive AgentsBehavior, AnimalExcitatory Postsynaptic PotentialsHippocampusInhibitory Concentration 50KetamineMaleMiceN-MethylaspartateProtein SubunitsPyramidal CellsRatsReceptors, N-Methyl-D-AspartateXenopus laevisAntidepressive AgentsKetamineN-MethylaspartateProtein SubunitsReceptors, N-Methyl-D-AspartateantidepressantdepressionhydroxynorketamineketamineNMDA receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05864053ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.